Trial Profile
A study comparing treatment response of RA patients using intravenous tocilizumab (TOC) as the first biologic agent with those who had prior exposure to other biologic agents: The Korean College of Rheumatology Biologics Registry (KOBIO)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Jul 2018
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 15 Jul 2018 New trial record
- 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism